1. Pneumonia caused by other viruses, except for 2019-nCov, 2. Clear bacterial infection, 3. Subjects who have used antiviral drugs and may need another antiviral treatment during the study, 4. There are serious non-infectious pulmonary diseases, including tuberculosis, pulmonary edema and pulmonary embolism, 5. Severe liver and kidney dysfunction, 6. Participating in other clinical studies within 30 days before administration, 7. Allergic to type 1 interferon, 8. Pregnant or lactating women, 9.In any other case, if the investigator thinks it is not suitable for the trial, or it may increase the risk of the subject or interfere with the clinical trial.

1. Pneumonia caused by other viruses, except for 2019-nCov, 2. Clear bacterial infection, 3. Subjects who have used antiviral drugs and may need another antiviral treatment during the study, 4. There are serious non-infectious pulmonary diseases, including tuberculosis, pulmonary edema and pulmonary embolism, 5. Severe liver and kidney dysfunction, 6. Participating in other clinical studies within 30 days before administration, 7. Allergic to type 1 interferon, 8. Pregnant or lactating women, 9.In any other case, if the investigator thinks it is not suitable for the trial, or it may increase the risk of the subject or interfere with the clinical trial.